Company Profile

Flex Biomedical Inc
Profile last edited on: 8/7/12      CAGE: 4X8F4      UEI:

Business Identifier: innovative products for the treatment and diagnosis of orthopedic injuries and diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

555 D’onofrio Drive Suite 10
Madison, WI 53719
   (608) 213-8246
Location: Single
Congr. District: 02
County: Dane

Public Profile

Formerly located in Boston, MA, Flex Biomedical Inc relocated to WI in 2009. Flex Biomedical is developing novel treatments and diagnostics for orthopedic conditions. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer™, designed to treat osteoarthritis, an incurable joint disease. Osteoarthritis is incurable, chronic , aused by a breakdown of cartilage and synovial fluid in the joints. Traditionally, osteoarthritis is treated with hyaluronic acid (HA) viscosupplements injected into the joint to try to improve the viscosity of the synovial fluid and reduce pain and swelling in the joint. However, injected HA only stays in the joint for one to two days and often is ineffective. Some trials have shown no superior benefit when compared to placebo. Flex Biomedical's polymer was designed to be a superior viscosupplement. We believe the polymer can both relieve pain and protect cartilage from further degradation, slowing down the progression of osteoarthritis - something current viscosupplement products cannot do. The Flex Polymer is a superior lubricant with a low coefficient of friction, exhibiting superior cushioning ability with non-linear viscosity during high-impact joint loads and shear strain. It is slow-degrading, which means it should last longer in the joint than HA products and can be synthetically manufactured much less expensively than HA products. Regulated as a medical device in the United States with a straight-forward approval path, on vitro and in vivo tests have confirmed the polymer's superior mechanical properties and its biocompatibility. Cytotoxicity, genotoxicity, sensitization, irritation, acute toxicity and other biocompatibility tests have been conducted, demonstrating the polymer's safety.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2008 1 NIH $175,140
Project Title: Synthetic Viscosupplement For Treating Osteoarthritis

Key People / Management

  Salvatore Braico -- President

  Hideki Suzuki

Company News

There are no news available.